

CITATION REPORT

List of articles citing

Lupus: improving long-term prognosis

DOI: 10.1177/0961203307087612

Lupus, 2008, 17, 166-70.

Source: <https://exaly.com/paper-pdf/44630531/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
45	Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. <i>Autoimmunity Reviews</i> , 2008 , 8, 1-4	13.6	57
44	Infections as triggers and complications of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2008 , 8, 24-8	13.6	132
43	Exploring the complex relationships between infections and autoimmunity. <i>Autoimmunity Reviews</i> , 2008 , 8, 89-91	13.6	28
42	Primary prevention of systemic lupus erythematosus. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 576-7		10
41	Atherosclerosis and lupus: what we know and what we should know. <i>Journal of Rheumatology</i> , 2009 , 36, 2380-2	4.1	11
40	Protective molecules and their cognate antibodies: new players in autoimmunity. <i>Autoimmunity Highlights</i> , 2010 , 1, 63-72	3.7	2
39	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , 2010 , 9, 849-52	13.6	58
38	SLE diagnosis and treatment: when early is early. <i>Autoimmunity Reviews</i> , 2010 , 10, 55-60	13.6	111
37	Infections and autoimmunity: the multifaceted relationship. <i>Journal of Leukocyte Biology</i> , 2010 , 87, 385-95	13.6	146
36	Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010,		22
35	Oxidative stress and homocysteine metabolism in patients with lupus nephritis. <i>Lupus</i> , 2010 , 19, 65-72	2.6	31
34	Current and novel therapeutics in the treatment of systemic lupus erythematosus. <i>Journal of Allergy and Clinical Immunology</i> , 2011 , 127, 303-12; quiz 313-4	11.5	121
33	Cricoarytenoiditis as an initial manifestation of systemic lupus erythematosus. <i>Case Reports in Rheumatology</i> , 2011 , 2011, 317379	0.8	1
32	Refractory disease in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2011 , 10, 685-92	13.6	15
31	The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2011 , 10, 674-8	13.6	24
30	A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. <i>Arthritis Care and Research</i> , 2011 , 63, 1224-32	4.7	50
29	Immunotherapeutic Agents for SLE. 2012 ,		

28	Epratuzumab in SLE. 2012 , 56-68			1
27	Immunopathogenesis of SLE & drug targets. 2012 , 8-30			
26	Other novel immunotherapeutic agents in the pipeline and future directions. 2012 , 80-90			
25	Intravenous immunoglobulin therapy for SLE. 2012 , 70-78			
24	Rituximab in SLE. 2012 , 32-41			
23	Controversies in rheumatism and autoimmunity. <i>Autoimmunity Reviews</i> , 2012 , 11, 555-7	13.6		5
22	Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 41, 830-9	5.3		135
21	Human papillomavirus vaccine and systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2013 , 32, 1301-7	3.9		84
20	[Infections in patients affected by rheumatologic diseases associated to glucocorticoid use or tumor necrosis factor-alpha inhibitors]. <i>Revista Chilena De Infectologia</i> , 2014 , 31, 181-95	0		3
19	Patterns of systemic lupus erythematosus expression in Europe. <i>Autoimmunity Reviews</i> , 2014 , 13, 621-9	13.6		53
18	Sifalimumab, an anti-interferon- γ monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1909-1916	2.4		309
17	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , 2016 , 55, 1243-50	3.9		19
16	Anifrolumab, an Anti-Interferon- γ Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017 , 69, 376-386	9.5		430
15	Biological Features of IL-12 and IFN- γ in the Pathogenesis of Systematic Lupus Erythematosus. 2017 , 07,			
14	Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea. <i>Patient Preference and Adherence</i> , 2017 , 11, 1779-1787	2.4		1
13	Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2018 , 28, 986-992	3.3		28
12	Can we manage lupus nephritis without chronic corticosteroids administration?. <i>Autoimmunity Reviews</i> , 2018 , 17, 4-10	13.6		24
11	Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1025-1029	5.3		10

10	New therapeutic strategies in systemic lupus erythematosus management. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 30-48	8.1	58
9	Safety and tolerability of sifalimumab, an anti-interferon- γ monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. <i>Modern Rheumatology</i> , 2020 , 30, 93-100	3.3	12
8	Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2020 , 39, 2619-2629	3.9	4
7	Introduction: Metrics and Domains Measured in SLE. 2021 , 1-28		
6	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 560-575	2	1
5	Immunotherapeutic agents for SLE. 2012 , 2-6		
4	Index. 2012 , 92-93		
3	Belimumab in SLE. 2012 , 42-54		
2	Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.. <i>ACR Open Rheumatology</i> , 2022 ,	3.5	2
1	Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades. 2022 , 61, 3189-3196		1